Ozone in COVID-19

Excerpt:


J Pharm Pharmacogn Res 9(2): 126-142, 2021. Original Article Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study [Aplicación de la solución salina ozonizada como terapia complementaria en pacientes COVID-19 con neumonía de estadía mediana a severa: Estudio piloto no aleatorizado] Adriana Schwartz1,Gregorio Martínez-Sánchez2*, Alejandra M. de … Continue reading Ozone in COVID-19


J Pharm Pharmacogn Res 9(2): 126-142, 2021.

Original Article

Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study

[Aplicación de la solución salina ozonizada como terapia complementaria en pacientes COVID-19 con neumonía de estadía mediana a severa: Estudio piloto no aleatorizado]

Adriana Schwartz1,Gregorio Martínez-Sánchez2*, Alejandra M. de Lucía3, Sergio M. Viana4, Alina M. Constanta5

1Fiorella Clinic, Pain Management Unit, Madrid (28035), Spain.

2Scientific advisor, Freelance, Ancona (60126), Italy.

3Integrative Medicine Clinic, Madrid (28002), Spain.

4Cardio Care of Hospital High Care Marbella and Hospital CHIP of Malaga (29010), Spain.

5Hospital Virgen De La Paloma, Madrid (28003) Spain.

*E-mail: gregorcuba@yahoo.it

Abstract

Context: Currently, there is no effective antiviral therapy recommended for novel coronavirus pneumonia 2019 (COVID-19).

Aims: To assess the safety of ozonized saline solution (O3SS) used as a complementary therapy in adult COVID-19 patients.

Methods: Twenty-five adult patients hospitalized with mild to severe symptoms of COVID-19, who met the inclusion criteria and were treated from April 18 to April 26, 2020, at Virgen De La Paloma Hospital, Madrid, Spain were included in this study. Patients were assigned to receive standard care consisting ceftriaxone (250 mg – 2 g twice daily for 7 days) plus azithromycin (500 mg once daily for 5 days), of 200 – 400 mg hydroxychloroquine twice daily for 5-7 days plus tocilizumab 400 mg twice daily for 5 days, low molecular weight heparin and 40 to 60 mg metil-prednisone plus O3SS, 200 mL, 3-5 µg/mL per day for 10 days. No control group was included, the data was compared to clinical trials in this subject. Secondary endpoints assessed included the clinical status of participants, laboratory examinations, and duration of viral shedding.

Results: Patients with COVID-19 with mild to severe symptoms who received intravenous O3SS as an adjunct treatment experienced no side effects. The main results of O3SS treatment were a tendency to improve clinical symptoms without side effects. None of the patients treated died.

Conclusions: Early evidence of efficacy shown improvements in symptoms such as dyspnea, weakness, and reduction in body temperature were observed and corresponded to improvements in laboratory results including D-dimer, fibrinogen, lactate dehydrogenase, and C-reactive protein. These preliminary data will serve as the basis for a future study of the effectiveness of this therapy.

Keywords: COVID-19; ozone therapy; ozonized saline solution; pneumonia; SARS-CoV-2.

This image has an empty alt attribute; its file name is jppres_pdf_free.png
Resumen

Contexto: Actualmente, no existe una terapia antiviral eficaz recomendada para la neumonía por el nuevo coronavirus 2019 (COVID-19).

Objetivos: Evaluar la seguridad de la solución salina ozonizada (O3SS) como terapia complementaria en pacientes adultos con COVID-19.

Métodos: Se incluyeron veinticinco pacientes adultos con síntomas leves a severos de COVID-19, que cumplieron con los criterios de inclusión. Estos fueron tratados del 18 al 26 de abril de 2020, en el Hospital Virgen de La Paloma, Madrid, España. Los pacientes fueron asignados para recibir atención estándar [ceftriaxona (250 mg – 2 g cada 12 h por 7 días); azitromicina (500 mg cada 24 h por 5 días); 200-400 mg de hidroxicloroquina cada 12 h por 5-7 días; tocilizumab 400 mg cada 12 h por 5 días; heparina y 40 a 60 mg de metil-prednisona] más O3SS, 200 mL, 3-5 µg/mL por día durante 10 días. No se incluyó ningún grupo de control, los datos se compararon con ensayos clínicos similares. Los criterios de valoración secundarios incluyeron el estado clínico de los participantes, los exámenes de laboratorio y la duración de la diseminación viral.

Resultados: Los pacientes con COVID-19 tratados que recibieron O3SS intravenoso como tratamiento complementario no experimentaron efectos secundarios. El tratamiento con O3SS tendió a mejorar los síntomas clínicos. Ninguno de los pacientes tratados falleció.

Conclusiones: Se observaron evidencias tempranas de mejoras en síntomas como disnea, debilidad y reducción de la temperatura corporal, que correspondieron con una mejora de variables como: el dímero D, fibrinógeno, lactato deshidrogenasa y proteína C reactiva. Estos datos preliminares servirán de base para un futuro estudio de la eficacia de esta terapia.

Palabras Clave: Clave: COVID-19; ozonoterapia; solución salina ozonizada, neumonía; SARS-CoV-2.

This image has an empty alt attribute; its file name is jppres_pdf_free.png
Citation Format: Schwartz A, Martínez-Sánchez G, de Lucía AM, Viana SM, Constanta AM (2021) Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study. J Pharm Pharmacogn Res 9(2): 126–142.

© 2021 Journal of Pharmacy & Pharmacognosy Research (JPPRes)

System optimization and validation of roselle
J. Pharm. Pharmacogn. Res., vol. 11, no. 2, pp. 243-254, March-April 2023. DOI: https://doi.org/10.56499/jppres22.1566_11.2.243 Original Article System optimization and validation to improve thin-layer chromatography of roselle calyces (Hibiscus sabdariffa L.) required by the Indonesian Herbal Pharmacopoeia Edition II [Optimización y validación del sistema para mejorar la cromatografía en capa fina de cálices de rosa mosqueta (Hibiscus … Continue reading System optimization and validation of roselle
Chitosan-alginate scaffold with Zingiber officinale for neural tissue engineering
J. Pharm. Pharmacogn. Res., vol. 11, no. 2, pp. 229-242, March-April 2023. DOI: https://doi.org/10.56499/jppres22.1505_11.2.229 Original Article Chitosan–alginate porous scaffold incorporated with hydroalcoholic Zingiber officinale Roscoe extract for neural tissue engineering [Estructura porosa de quitosano-alginato incorporada con extracto hidroalcohólico de Zingiber officinale Roscoe para la ingeniería del tejido neural] Hassan Sohrabian Kafraj1, Maryam Alipour2, Abdolhosein Shiravi1, Vida … Continue reading Chitosan-alginate scaffold with Zingiber officinale for neural tissue engineering
Ilex paraguariensis and eggshell membrane vs. aging
J. Pharm. Pharmacogn. Res., vol. 11, no. 2, pp. 216-228, March-April 2023. DOI: https://doi.org/10.56499/jppres22.1509_11.2.216 Original Article Oral supplementation of Ilex paraguariensis extract and eggshell membrane exhibit beneficial effects on the skin of mature male rats [La suplementación oral de extracto de Ilex paraguariensis y membrana de cáscara de huevo muestran efectos beneficiosos sobre la piel de … Continue reading Ilex paraguariensis and eggshell membrane vs. aging

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio